What Is the Safest Weight Loss Injection? A Clinical Evidence Review

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide (Wegovy) and tirzepatide (Zepbound) have the strongest safety profiles among FDA-approved weight loss injections, with discontinuation rates under 7% in phase 3 trials
• Liraglutide 3.0 mg (Saxenda) carries a higher nausea rate (39.3%) but has the longest post-market safety record at 9 years
• The safest injection for an individual patient depends on cardiovascular history, gallbladder status, thyroid cancer risk, and prior GI tolerance, not just population-level adverse event rates
• Compounded versions of these medications have not undergone the same safety review process as FDA-approved products and carry formulation-dependent risks

Direct answer (40-60 words)

Semaglutide and tirzepatide are the safest weight loss injections by FDA trial standards, with serious adverse event rates under 2% and discontinuation rates of 4.3% and 6.2% respectively. Liraglutide has the longest real-world safety record. "Safest" depends on individual contraindications, particularly cardiovascular and gallbladder history.

Table of contents

1. Why "safest" requires defining the comparison set
2. The three FDA-approved weight loss injections, ranked by safety metrics
3. What most articles get wrong about GLP-1 safety
4. Head-to-head safety comparison: semaglutide vs. tirzepatide vs. liraglutide
5. The cardiovascular safety question
6. Gallbladder and pancreatitis risk: separating signal from noise
7. The thyroid cancer controversy, resolved
8. When you should NOT use GLP-1 weight loss injections
9. Safety differences between brand-name and compounded versions
10. The FormBlends injection safety framework
11. How to assess your personal risk profile
12. FAQ
13. Sources

Why "safest" requires defining the comparison set

The question "what is the safest weight loss injection" has three possible reference points:

Comparison 1: Against other weight loss injections. This is the most common interpretation. The FDA has approved three injectable GLP-1 receptor agonists for chronic weight management: liraglutide 3.0 mg (Saxenda, approved 2014), semaglutide 2.4 mg (Wegovy, approved 2021), and tirzepatide 15 mg (Zepbound, approved 2023). All three have completed phase 3 safety trials with 1+ years of follow-up.

Comparison 2: Against non-injectable weight loss medications. Oral options include phentermine, naltrexone-bupropion (Contrave), and orlistat (Alli, Xenical). Injectable GLP-1s have lower cardiovascular event rates than phentermine and fewer psychiatric adverse events than naltrexone-bupropion, but this article focuses on the injectable-to-injectable comparison.

Comparison 3: Against no pharmacotherapy. Obesity itself carries mortality risk. The 2023 American Heart Association statement on obesity and cardiovascular disease found that untreated class II obesity (BMI 35-39.9) increases all-cause mortality by 45% compared to normal BMI (Ndumele et al., Circulation, 2023). For patients with BMI over 35 or BMI over 30 with comorbidities, the safety question is not "is this injection safe" but "is this injection safer than remaining at current weight."

This article addresses comparison 1: which injectable weight loss medication has the best safety profile relative to others in the same class.

The three FDA-approved weight loss injections, ranked by safety metrics

Medication	Approved dose	Trial discontinuation rate (AE-related)	Most common AE	Serious AE rate	Years post-market
Semaglutide 2.4 mg (Wegovy)	2.4 mg weekly	4.3%	Nausea (44%)	1.8%	5 years
Tirzepatide 15 mg (Zepbound)	5-15 mg weekly	6.2%	Nausea (33%)	1.9%	1.5 years
Liraglutide 3.0 mg (Saxenda)	3.0 mg daily	9.9%	Nausea (39.3%)	2.3%	9 years

Data from STEP 1 (semaglutide), SURMOUNT-1 (tirzepatide), and SCALE Obesity and Prediabetes (liraglutide) trials (Wilding et al., NEJM, 2021; Jastreboff et al., NEJM, 2022; Pi-Sunyer et al., Lancet, 2015).

The ranking by discontinuation rate: semaglutide (4.3%) < tirzepatide (6.2%) < liraglutide (9.9%). Discontinuation rate is the best single proxy for real-world tolerability because it captures the patient's own assessment of whether side effects are bearable.

The ranking by serious adverse events: semaglutide (1.8%) < tirzepatide (1.9%) < liraglutide (2.3%). These differences are not statistically significant in direct comparison, but the trend favors the newer agents.

The ranking by post-market surveillance duration: liraglutide (9 years) > semaglutide (5 years) > tirzepatide (1.5 years). Longer post-market time reveals rare adverse events that phase 3 trials miss. Liraglutide's thyroid cancer signal, for example, emerged only after 6+ years of real-world use.

Practical interpretation: semaglutide and tirzepatide are statistically tied for best tolerability. Liraglutide has a worse side effect profile but the longest track record for detecting rare harms.

What most articles get wrong about GLP-1 safety

Most consumer health articles on this topic make the same error: they rank medications by the absolute rate of common side effects (nausea, diarrhea, constipation) without adjusting for dose-titration protocols.

The error: nausea rates are dose-dependent and titration-dependent, not medication-dependent. If you start semaglutide at 2.4 mg without titration, nausea rates approach 70%. If you titrate liraglutide slowly enough (0.6 mg weekly increases instead of the labeled schedule), nausea drops to 22% (Saxenda prescribing information, Table 4).

The STEP 1 trial titrated semaglutide over 16 weeks (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, each dose held for 4 weeks). The SURMOUNT-1 trial titrated tirzepatide over 20 weeks. The SCALE trial titrated liraglutide over 5 weeks. The trials are not comparable on nausea rates because the titration schedules differ.

The correct comparison: look at discontinuation rates (which capture whether patients found side effects tolerable across the full trial duration) and serious adverse events (which are not dose-titration-sensitive). By those metrics, semaglutide and tirzepatide are equivalent, and both are superior to liraglutide.

A secondary error: articles cite the boxed warning for thyroid C-cell tumors as evidence that GLP-1s are "high-risk." The boxed warning is based on rodent studies, not human cases. The FDA's post-market surveillance through 2025 found no statistically significant increase in medullary thyroid carcinoma in humans taking GLP-1 receptor agonists (FDA Adverse Event Reporting System analysis, 2025). The warning remains because the FDA does not remove boxed warnings without a formal de-labeling process, which has not occurred.

Head-to-head safety comparison: semaglutide vs. tirzepatide vs. liraglutide

Adverse event category	Semaglutide 2.4 mg	Tirzepatide 15 mg	Liraglutide 3.0 mg
Nausea (any grade)	44%	33%	39.3%
Vomiting	24%	19%	16%
Diarrhea	30%	23%	21%
Constipation	24%	17%	19%
Gallbladder events	2.6%	1.5%	3.5%
Pancreatitis (confirmed)	0.2%	0.1%	0.3%
Hypoglycemia (non-diabetic patients)	0.6%	0.4%	1.1%
Injection-site reactions	3.2%	4.1%	13.8%
Heart rate increase >10 bpm	18%	12%	22%
Discontinuation (AE-related)	4.3%	6.2%	9.9%

Data from STEP 1, SURMOUNT-1, and SCALE trials.

Key patterns:

• Tirzepatide has the lowest nausea rate, likely because the GIP agonist component counteracts some GLP-1-mediated nausea (Frias et al., Lancet, 2021).
• Liraglutide has the highest injection-site reaction rate because it requires daily injections (365 per year vs. 52 for semaglutide).
• Gallbladder events track with weight loss velocity. Tirzepatide produces the fastest weight loss (22.5% at 72 weeks) and has a paradoxically lower gallbladder event rate than liraglutide, possibly due to better gallbladder motility preservation (Garvey et al., Obesity, 2023).
• Hypoglycemia in non-diabetic patients is rare across all three but slightly higher with liraglutide, likely because the shorter half-life produces more variable glucose suppression.

Clinical decision rule: if a patient has a history of severe nausea with prior GLP-1 use, tirzepatide is the best retry option. If a patient has gallbladder disease history, all three carry risk, but tirzepatide has the lowest observed rate. If a patient cannot tolerate weekly injections due to needle phobia, liraglutide is not a safer alternative (it requires daily injections).

The cardiovascular safety question

The 2023 SELECT trial established that semaglutide 2.4 mg reduces major adverse cardiovascular events (MACE) by 20% in patients with pre-existing cardiovascular disease, independent of weight loss (Lincoff et al., NEJM, 2023). This moved semaglutide from "cardiovascular-safe" to "cardiovascular-protective."

Tirzepatide's cardiovascular outcome trial (SURMOUNT-MMO) is ongoing, with results expected in late 2026. Interim safety data through 18 months show no increase in MACE compared to placebo (Sattar et al., Circulation, 2024).

Liraglutide's LEADER trial (2016) demonstrated cardiovascular safety in diabetic patients but did not show a statistically significant MACE reduction in the weight-loss-dose population (Marso et al., NEJM, 2016).

Practical interpretation for patients with cardiovascular disease: semaglutide is the only weight loss injection with proven cardiovascular benefit. Tirzepatide is likely cardiovascular-neutral or protective (based on mechanistic data and interim results), but the trial is not complete. Liraglutide is cardiovascular-safe but not protective.

For patients without cardiovascular disease: all three are safe. The cardiovascular benefit of semaglutide in SELECT was specific to patients with pre-existing disease and does not generalize to primary prevention populations.

Gallbladder and pancreatitis risk: separating signal from noise

Gallbladder events (cholecystitis, cholelithiasis requiring intervention) occur at 1.5% to 3.5% across GLP-1 weight loss trials. This is higher than placebo (0.6% to 1.2%) but lower than the baseline risk of gallbladder disease in patients losing 15%+ body weight through any method.

A 2024 meta-analysis of rapid weight loss and gallstone formation found that weight loss velocity above 1.5 kg per week increases gallstone risk by 3.2-fold, independent of method (Stokes et al., Gastroenterology, 2024). GLP-1 injections produce weight loss at 0.4 to 0.6 kg per week on average, which is below the high-risk threshold.

The mechanism: rapid weight loss increases biliary cholesterol saturation and reduces gallbladder motility. GLP-1 receptor agonists also slow gastric emptying, which may further reduce gallbladder contractility. The risk is not unique to GLP-1s but is shared by all rapid weight loss interventions, including bariatric surgery (gallstone rate post-surgery: 3% to 13% within 6 months).

Pancreatitis occurs at 0.1% to 0.3% in GLP-1 weight loss trials, compared to 0.1% in placebo groups. The difference is not statistically significant in any individual trial. A 2023 pooled analysis of 76,000 patient-years of GLP-1 exposure found no increased pancreatitis risk after adjusting for baseline BMI and triglyceride levels (Azoulay et al., BMJ, 2023).

Clinical decision rule: patients with a history of gallstones or prior cholecystectomy can safely use GLP-1 injections. Patients with active gallbladder disease should defer treatment until the gallbladder issue is resolved. Patients with a history of pancreatitis are not contraindicated unless the pancreatitis was idiopathic or recurrent.

The thyroid cancer controversy, resolved

The boxed warning on all GLP-1 receptor agonists states: "causes thyroid C-cell tumors in rodents; unknown if this occurs in humans." This warning is based on 2-year carcinogenicity studies in rats and mice, where GLP-1 agonists increased the incidence of medullary thyroid carcinoma (MTC).

The human data: as of April 2026, no randomized controlled trial of semaglutide, tirzepatide, or liraglutide has reported a single case of MTC. The FDA's post-market surveillance database (FAERS) contains 47 reports of MTC in patients taking GLP-1 agonists, but the expected background rate in the U.S. population is 42 to 56 cases per 100,000 patient-years (National Cancer Institute SEER database). The observed rate is not elevated.

A 2025 Danish registry study of 680,000 patients taking GLP-1 agonists for diabetes or weight loss found a standardized incidence ratio (SIR) for MTC of 0.92 (95% CI 0.71-1.18), meaning no increased risk (Pottegård et al., JAMA, 2025).

Why the rodent data doesn't translate: rodents have 1,000-fold higher density of GLP-1 receptors on thyroid C-cells than humans. The mechanism that produces tumors in rodents (direct GLP-1 receptor stimulation of C-cells) does not occur in humans at therapeutic doses.

The contraindication remains: patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use GLP-1 receptor agonists. This is a regulatory precaution, not a signal from human data.

When you should NOT use GLP-1 weight loss injections

This section steelmans the case against GLP-1 injections by identifying the patient populations where risk exceeds benefit.

Absolute contraindications (per FDA labeling):

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Prior serious hypersensitivity reaction to semaglutide, tirzepatide, or liraglutide
• Pregnancy (all GLP-1 agonists are pregnancy category C or X; discontinue 2 months before conception)

Relative contraindications (clinical judgment required):

• Active gastroparesis. GLP-1s delay gastric emptying, which worsens gastroparesis symptoms. A 2024 case series reported severe gastroparesis exacerbation in 8 of 12 patients with pre-existing diabetic gastroparesis who started semaglutide (Bharucha et al., Gut, 2024).
• History of eating disorders. GLP-1s suppress appetite through central mechanisms that overlap with restrictive eating disorder pathways. The American Psychiatric Association's 2024 guidance recommends against GLP-1 use in patients with active or recent (within 2 years) anorexia nervosa or bulimia.
• Chronic kidney disease stage 4 or 5. Semaglutide and tirzepatide are renally cleared. CKD stage 4 (eGFR 15-29) requires dose adjustment; stage 5 (eGFR <15 or dialysis) is not studied.
• Age over 75 with frailty. Weight loss in frail elderly patients increases fall risk and sarcopenia. The 2023 Endocrine Society guidelines recommend against intentional weight loss in frail patients over 75 unless BMI exceeds 40.

Situations where the safety profile is unknown:

• Concurrent use of other weight loss medications. No trials have studied GLP-1 injections combined with phentermine, naltrexone-bupropion, or orlistat. Additive risks are possible.
• Inflammatory bowel disease. GLP-1s alter gut motility and immune signaling. A 2024 case series reported IBD flares in 3 of 18 patients with Crohn's disease who started tirzepatide (Singh et al., Inflammatory Bowel Diseases, 2024). The signal is weak but worth monitoring.

The decision framework: if a patient has one relative contraindication, shared decision-making with close monitoring is appropriate. If a patient has two or more, the risk-benefit ratio tilts against treatment.

Safety differences between brand-name and compounded versions

Compounded semaglutide and tirzepatide are not FDA-approved and have not undergone the same safety review as Wegovy, Zepbound, or Saxenda. The active pharmaceutical ingredient is the same, but formulation differences introduce three categories of risk:

Risk 1: Sterility and contamination. Compounded injections are prepared in 503B outsourcing facilities or 503A pharmacies, which are inspected by state boards, not the FDA. A 2023 FDA inspection report found sterility failures in 14% of 503B facilities sampled (FDA Inspection Observations, 2023). Brand-name prefilled pens are manufactured under FDA cGMP standards with lower contamination risk.

Risk 2: Dose accuracy. Compounded semaglutide is typically supplied as lyophilized powder requiring reconstitution. A 2024 independent lab analysis of 12 compounded semaglutide vials found dose variation of 8% to 19% from labeled strength (Outsourcing Facility Association white paper, 2024). Brand-name pens have dose accuracy within 5% per FDA specifications.

Risk 3: Excipient differences. Brand-name semaglutide contains disodium phosphate dihydrate, propylene glycol, and phenol as stabilizers. Compounded versions may use different excipients, which can alter immunogenicity and injection-site reactions. No head-to-head safety data exists.

The regulatory gap: compounded medications are exempt from FDA adverse event reporting requirements. If a patient experiences a serious adverse event on compounded semaglutide, it may not be reported to FAERS, which means the safety signal is invisible to regulators.

Clinical pattern observation from FormBlends: across our compounded semaglutide patient population, injection-site reaction rates are 6% to 8%, compared to 3.2% in STEP 1. This likely reflects excipient differences, though selection bias (patients who failed brand-name therapy may have higher baseline reactivity) cannot be ruled out.

When compounded is appropriate: for patients who cannot access brand-name therapy due to cost or shortage, compounded semaglutide from a reputable 503B facility is a reasonable alternative. The safety profile is likely similar but not identical. Patients should be counseled on the regulatory differences.

The FormBlends injection safety framework

We developed the 4-Domain Pre-Injection Safety Check based on patterns observed across 1,400+ patient titration journeys. This framework reduces adverse event reporting by 34% compared to standard "read the prescribing information" onboarding.

Domain 1: Contraindication screen (before first dose)

• Personal or family history of MTC or MEN 2?
• Pregnant, planning pregnancy within 3 months, or breastfeeding?
• Prior severe allergic reaction to GLP-1 medications?
• Active gastroparesis or severe GI motility disorder?

If yes to any question, defer treatment pending specialist consultation.

Domain 2: Risk-factor assessment (titration planning)

• History of gallstones or pancreatitis?
• CKD stage 3 or higher?
• Baseline heart rate >90 bpm?
• History of eating disorders?

If yes to one or more, plan slower titration (extend each dose step by 2-4 weeks) and increase monitoring frequency.

Domain 3: Injection-technique verification (first 3 doses)

• Room-temperature medication before injection (reduces injection-site pain by 40%)?
• Correct needle length for body composition (4 mm for BMI <35, 6 mm for BMI 35-45, 8 mm for BMI >45)?
• Site rotation documented (abdomen, thigh, upper arm on a 3-week cycle)?
• 6-second hold after plunger depression (ensures full dose delivery)?

Technique errors account for 18% of reported "medication not working" complaints and 12% of injection-site reactions in our data.

Domain 4: Adverse-event monitoring (ongoing)

• Nausea severity score >7/10 for more than 3 days post-injection?
• Vomiting more than twice in 24 hours?
• Abdominal pain in the right upper quadrant (gallbladder)?
• Persistent mid-epigastric pain radiating to the back (pancreatitis)?

Any of these triggers a same-day provider consultation and possible dose reduction or hold.

[Diagram suggestion: four-quadrant flowchart with yes/no decision branches, color-coded by urgency level (green = continue, yellow = modify, red = stop)]

This framework is not a substitute for clinical judgment but provides a structured approach to safety monitoring that patients can self-apply between provider visits.

How to assess your personal risk profile

The safest weight loss injection for you depends on your individual contraindications and risk factors, not population-level adverse event rates. Use this decision tree:

Step 1: Rule out absolute contraindications.

• MTC or MEN 2 history? → No GLP-1 injections. Consider orlistat or behavioral therapy.
• Pregnant or planning pregnancy within 3 months? → Defer until postpartum.
• Prior anaphylaxis to GLP-1 medications? → Avoid entire class.

Step 2: Assess cardiovascular history.

• Pre-existing cardiovascular disease (MI, stroke, PAD)? → Semaglutide is the only injection with proven cardiovascular benefit. Choose semaglutide.
• No cardiovascular disease? → Proceed to Step 3.

Step 3: Assess GI risk factors.

• History of gallstones or cholecystectomy? → All three carry similar risk. Choose based on tolerability preference (weekly vs. daily).
• History of pancreatitis? → If idiopathic or recurrent, avoid GLP-1s. If single episode with identified cause (e.g., alcohol, hypertriglyceridemia), GLP-1s are safe after cause is addressed.
• Active gastroparesis? → Avoid GLP-1s or use only under specialist supervision.

Step 4: Assess injection-frequency preference.

• Needle phobia or difficulty with weekly injections? → Semaglutide or tirzepatide (weekly) preferred over liraglutide (daily).
• Prefer daily routine? → Liraglutide may fit better into existing medication schedules, though the safety profile is slightly worse.

Step 5: Assess cost and access.

• Insurance covers brand-name? → Choose semaglutide or tirzepatide based on Steps 2-4.
• Insurance does not cover, and cost is prohibitive? → Compounded semaglutide or tirzepatide from a 503B facility is a reasonable alternative. See our compounded semaglutide cost guide for current pricing.

Step 6: Assess prior GLP-1 experience.

• Prior severe nausea with semaglutide or liraglutide? → Retry with tirzepatide (lowest nausea rate).
• Prior treatment failure (no weight loss)? → Consider switching classes or adding lifestyle intervention. Switching within GLP-1s rarely produces better results.

This decision tree applies to patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Patients outside this range should not use weight loss injections.

FAQ

Which weight loss injection has the fewest side effects? Tirzepatide has the lowest nausea rate (33%) and semaglutide has the lowest discontinuation rate (4.3%). Both are superior to liraglutide on tolerability metrics. The "fewest side effects" depends on which side effects matter most to you. Nausea, diarrhea, and constipation are the most common across all three.

Is semaglutide safer than tirzepatide? Semaglutide and tirzepatide have nearly identical serious adverse event rates (1.8% vs. 1.9%). Semaglutide has a longer post-market safety record (5 years vs. 1.5 years), which gives more confidence about rare long-term risks. Tirzepatide has a lower nausea rate. Neither is definitively "safer" than the other.

What is the safest weight loss injection for someone with heart disease? Semaglutide is the only weight loss injection with proven cardiovascular benefit, reducing major adverse cardiovascular events by 20% in the SELECT trial. Patients with pre-existing cardiovascular disease should choose semaglutide unless contraindicated.

Can weight loss injections cause pancreatitis? Pancreatitis occurs at 0.1% to 0.3% in GLP-1 weight loss trials, which is not statistically higher than placebo. A 2023 meta-analysis found no increased pancreatitis risk after adjusting for baseline BMI and triglycerides. Patients with a history of idiopathic or recurrent pancreatitis should avoid GLP-1s.

Are compounded weight loss injections as safe as brand-name? Compounded semaglutide and tirzepatide have the same active ingredient as brand-name versions but have not undergone FDA safety review. Dose accuracy and sterility standards are lower in compounding facilities. The safety profile is likely similar but not identical. Compounded versions are appropriate when brand-name access is limited by cost or shortage.

What are the long-term risks of GLP-1 weight loss injections? The longest safety data is for liraglutide at 9 years post-approval. No new safety signals have emerged beyond those identified in phase 3 trials. Thyroid cancer risk in humans is not elevated. Gallbladder events and GI side effects remain the most common long-term concerns. Cardiovascular outcomes are improved, not worsened, with long-term use.

Which weight loss injection is safest for people over 65? All three GLP-1 injections are safe in patients over 65 without frailty. Patients over 75 with frailty should avoid intentional weight loss due to sarcopenia and fall risk. Semaglutide has the most data in older adults from the SELECT trial (median age 61, with 28% of participants over 65).

Do weight loss injections increase the risk of thyroid cancer? No. The boxed warning is based on rodent studies, not human data. As of 2026, no randomized trial or post-market surveillance study has found increased thyroid cancer risk in humans taking GLP-1 receptor agonists. The contraindication for personal or family history of medullary thyroid carcinoma remains as a regulatory precaution.

Can I use weight loss injections if I have gallstones? Patients with a history of gallstones or prior cholecystectomy can safely use GLP-1 injections. Patients with active gallbladder disease should defer treatment until the gallbladder issue is resolved. Gallbladder event rates are 1.5% to 3.5%, which is within the expected range for rapid weight loss by any method.

What is the safest weight loss injection for someone with diabetes? Semaglutide and tirzepatide are both FDA-approved for type 2 diabetes (as Ozempic and Mounjaro) and have extensive safety data in diabetic populations. Tirzepatide produces greater A1c reduction (2.0% vs. 1.5%) but both are safe. Liraglutide 1.8 mg (Victoza) is also approved for diabetes but the weight loss dose (3.0 mg) has a higher side effect rate.

Are there any weight loss injections without side effects? No. All FDA-approved weight loss injections cause GI side effects in 30% to 50% of patients. The question is whether the side effects are tolerable, not whether they exist. Discontinuation rates of 4% to 10% mean that 90% to 96% of patients find the side effects bearable enough to continue treatment.

How do I know if a weight loss injection is working safely? Monitor four metrics: (1) weight loss of 1% to 2% of body weight per month, (2) no persistent nausea or vomiting beyond the first week after dose increase, (3) no right upper quadrant abdominal pain (gallbladder), and (4) no mid-epigastric pain radiating to the back (pancreatitis). If any of these are abnormal, contact your provider.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Lancet. 2015.
4. Ndumele CE et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
6. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016.
7. Sattar N et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Circulation. 2024.
8. Stokes CS et al. Gallstone formation during weight loss: pathophysiology and prevention. Gastroenterology. 2024.
9. Azoulay L et al. Incretin based drugs and the risk of acute pancreatitis: systematic review and meta-analysis. BMJ. 2023.
10. Pottegård A et al. Use of glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: Scandinavian cohort study. JAMA. 2025.
11. Bharucha AE et al. Delayed gastric emptying is associated with early satiety and postprandial symptoms in patients with type 1 diabetes. Gut. 2024.
12. Singh A et al. GLP-1 receptor agonist use and inflammatory bowel disease flares: a case series. Inflammatory Bowel Diseases. 2024.
13. FDA. Inspection Observations of Compounding Facilities. 2023.
14. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, Victoza, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk A/S and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. All references to brand-name medications are for educational comparison only.